We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
While access to cardiovascular drugs in lower-income countries has expanded, a significant gap still exists between access afforded to them and the access enjoyed by higher-income nations when it comes to these medications. Read More
AZ’s phase 3 trial failed to meet primary endpoints as required to keep its approval for the drug for previously treated adults with locally advanced or metastatic bladder cancer. Read More
Pfizer has allegedly demanded that certain Latin American governments put up assets as collateral in order to secure supply deals of its COVID-19 vaccine, a nonprofit investigative news organization in the UK has claimed. Read More
Cognate is expected to generate revenue of approximately $140 million in 2021 and to grow by at least 25 percent annually over the next five years. Read More
AbbVie and Medytox have settled with Evolus over allegations that it and Daewoong Pharmaceuticals had pilfered trade secrets in order to market a competitor to AbbVie’s Botox wrinkle treatment called Jeuveau. Read More
GSK will pay $225 million upfront and make a $120 million equity investment in Vir and could pay an additional $500 million in development options. Read More
Eli Lilly has inked a global licensing deal with Rigel Pharmaceuticals for the company’s investigational anti-inflammatory drug, R552, in a pact worth potentially $960 million. Read More
GlaxoSmithKline (GSK) and Vir Biotechnology have teamed up to develop monoclonal antibodies for respiratory viruses, building off an existing agreement struck last year to develop COVID-19 therapies. Read More
The World Health Organization (WHO)’s COVAX initiative is set to begin distributing vaccines to low- and middle-income nations this month, following the organization’s approval of an emergency-use listing of the AstraZeneca (AZ)/Oxford vaccine. Read More